SEC Filing Summary

Ryan Lynch, Treasurer, Senior Vice President of Finance and Chief Accounting Officer of CRESCENT BIOPHARMA, INC., reported the sale of 465 ordinary shares on June 22, 2026. The shares were automatically sold to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sales were effected pursuant to a Rule 10b5-1 instruction adopted on February 25, 2026, solely to cover taxes related to the vesting of restricted stock units. The reported price of $17.99 is a weighted average, with actual sale prices ranging from $16.88 to $18.86. Following the transaction, Lynch holds 13,871 shares.